-
1
-
-
80053088189
-
Hepatocellular carcinoma
-
El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
-
(2011)
N Engl J Med
, vol.365
, pp. 1118-1127
-
-
El-Serag, H.B.1
-
2
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
De Oliveira, A.C.7
Santoro, A.8
Raoul, J.L.9
Forner, A.10
Schwartz, M.11
Porta, C.12
Zeuzem, S.13
Bolondi, L.14
Greten, T.F.15
Galle, P.R.16
Seitz, J.F.17
Borbath, I.18
Häussinger, D.19
Giannaris, T.20
Shan, M.21
Moscovici, M.22
Voliotis, D.23
Bruix, J.24
more..
-
3
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
DOI 10.1200/JCO.2005.01.3441
-
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006. (Pubitemid 46630787)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.26
, pp. 4293-4300
-
-
Abou-Alfa, G.K.1
Schwartz, L.2
Ricci, S.3
Amadori, D.4
Santoro, A.5
Figer, A.6
De Greve, J.7
Douillard, J.-Y.8
Lathia, C.9
Schwartz, B.10
Taylor, I.11
Moscovici, M.12
Saltz, L.B.13
-
4
-
-
84867843356
-
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
-
Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC and Galmiche A: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131: 2961-2969, 2012.
-
(2012)
Int J Cancer
, vol.131
, pp. 2961-2969
-
-
Ezzoukhry, Z.1
Louandre, C.2
Trécherel, E.3
Godin, C.4
Chauffert, B.5
Dupont, S.6
Diouf, M.7
Barbare, J.C.8
Mazière, J.C.9
Galmiche, A.10
-
5
-
-
77952329787
-
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
-
Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S and Loda M: Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA 107: 8352-8356, 2010.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 8352-8356
-
-
Vaira, V.1
Fedele, G.2
Pyne, S.3
Fasoli, E.4
Zadra, G.5
Bailey, D.6
Snyder, E.7
Faversani, A.8
Coggi, G.9
Flavin, R.10
Bosari, S.11
Loda, M.12
-
6
-
-
84864285794
-
Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion
-
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA and Golub TR: Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504, 2012.
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
Morikawa, T.2
Shee, K.3
Barzily-Rokni, M.4
Qian, Z.R.5
Du, J.6
Davis, A.7
Mongare, M.M.8
Gould, J.9
Frederick, D.T.10
Cooper, Z.A.11
Chapman, P.B.12
Solit, D.B.13
Ribas, A.14
Lo, R.S.15
Flaherty, K.T.16
Ogino, S.17
Wargo, J.A.18
Golub, T.R.19
-
7
-
-
84862908097
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
-
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A and Marais R: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207-215, 2012.
-
(2012)
N Engl J Med
, vol.366
, pp. 207-215
-
-
Su, F.1
Viros, A.2
Milagre, C.3
Trunzer, K.4
Bollag, G.5
Spleiss, O.6
Reis-Filho, J.S.7
Kong, X.8
Koya, R.C.9
Flaherty, K.T.10
Chapman, P.B.11
Kim, M.J.12
Hayward, R.13
Martin, M.14
Yang, H.15
Wang, Q.16
Hilton, H.17
Hang, J.S.18
Noe, J.19
Lambros, M.20
Geyer, F.21
Dhomen, N.22
Niculescu-Duvaz, I.23
Zambon, A.24
Niculescu-Duvaz, D.25
Preece, N.26
Robert, L.27
Otte, N.J.28
Mok, S.29
Kee, D.30
Ma, Y.31
Zhang, C.32
Habets, G.33
Burton, E.A.34
Wong, B.35
Nguyen, H.36
Kockx, M.37
Andries, L.38
Lestini, B.39
Nolop, K.B.40
Lee, R.J.41
Joe, A.K.42
Troy, J.L.43
Gonzalez, R.44
Hutson, T.E.45
Puzanov, I.46
Chmielowski, B.47
Springer, C.J.48
McArthur, G.A.49
Sosman, J.A.50
Lo, R.S.51
Ribas, A.52
Marais, R.53
more..
-
8
-
-
0029778988
-
An algorithm for the grading of activity in chronic hepatitis C
-
DOI 10.1053/jhep.1996.v24.pm0008690394
-
Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293, 1996. (Pubitemid 26260021)
-
(1996)
Hepatology
, vol.24
, Issue.2
, pp. 289-293
-
-
Bedossa, P.1
Poynard, T.2
|